期刊文献+

可溶性人sPD-L1及其抗体的制备和鉴定 被引量:3

Preparation and Identification of Human Soluble sPD-L1 and Its Antibodies
下载PDF
导出
摘要 通过固定化金属离子亲和层析进行柱上复性与纯化,获得高纯度的可溶性PD-L1胞外域(sPD-L1),其纯度达95%,纯化的sPD-L1经免疫印迹分析得到验证,并具有与其受体PD-1的特异性结合活性;以该抗原免疫小鼠获得高滴度的抗血清,并以制备的sPD-L1-HiTrap亲和层析柱纯化获得高纯度特异性抗体;将该抗体与另一商业化抗体结合建立了一种灵敏的双夹心ELISA法,检测范围为1ng/mL^100ng/mL,可用于分析可溶性PD-L1的含量。可溶性sPD-L1及其抗体的制备不仅可用于人体内特异性抗体和可溶性PD-L1的检测,同时也为进一步研究其体内外活性及其受体的性质提供了条件。 This study reports the preparation and identification of soluble programmed death-1 (PD-1) ligand-1 (sPD-L1) and its antibodies of mouse origin. Immobilized metal ion affinity chromatography was used to perform on-column refolding with simultaneous purification of denatured sPD-L1, and soluble sPD-L1 with purity of 95 % was obtained. The purified sPD-L1 was verified by immunoblotting using a commercial goat-anti-human PD-L1 antibody. An ELISA-based assay showed that it also had high binding activity for its cognate receptor PD-1. Furthermore, mouse anti-sPD-L1 antiserum of high titer was raised using the purified sPD-L1 as an immunogen, and the specific IgG antibodies were purified using sPD-L1-HiTrap affinity chromatography. In addition, a sensitive sandwich ELISA was established using the purified IgG antibodies together with the commercial goat antibodies. In conclusion, the preparation of soluble sPD-L1 and its antibodies provide the basis for detection of the potential anti-PD-L1 antibodies and soluble PD-L1 in humans as well as for further investigation of its in vivo bioactivities and characterization of its potential receptors.
出处 《生物工程学报》 CAS CSCD 北大核心 2007年第1期106-111,共6页 Chinese Journal of Biotechnology
基金 国家自然科学基金(No.30572199和30371651)资助项目~~
关键词 PD-L1 原核表达 重折叠 亲和层析 抗体 PD-L1, prokaryotic expression, refolding, affinity chromatography, antibody
  • 相关文献

参考文献5

二级参考文献28

  • 1何贤辉,徐丽慧,刘毅,蔡小嫦,曾耀英.人PD-L1 cDNA的克隆及其胞外区蛋白在大肠杆菌中的表达[J].细胞与分子免疫学杂志,2004,20(6):659-663. 被引量:4
  • 2贺宇飞,张桂梅,王小红,张慧,袁野,李东,冯作化.重组可溶性PD-1免疫抑制性受体增强抗小鼠H22肝癌的免疫效应[J].中国肿瘤生物治疗杂志,2004,11(4):272-276. 被引量:2
  • 3徐丽慧,洪岸,何贤辉.人EGF受体胞外域cDNA克隆及其序列分析[J].暨南大学学报(自然科学与医学版),2005,26(2):168-173. 被引量:6
  • 4Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance[J]. Trends Immunol, 2001, 22(5): 265-268.
  • 5Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor[J]. Immunity, 1999, 11(2): 141-151.
  • 6Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice[J]. Science, 2001, 291(5502): 319-322.
  • 7Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7): 1027-1034.
  • 8Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses[J]. Ann Rev Immunol, 2002, 20: 29-53.
  • 9Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival[J]. Transplantation, 2003, 76(6): 994-999.
  • 10Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12): 1365-1369.

共引文献14

同被引文献15

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部